Myriad Genetics MYGN Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

NeoGenomicsNEO

——

Castle BiosciencesCSTL

——

Other financials

Income statement

See full

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

See full

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

See full

Operating cash flow-$15.7M+3.7%

CapEx$18.8M+181%

Free cash flow-$19.7M+65.1%

Valuation

See full

Market cap$512.85M+13.1%

Enterprise value$598.35M+17.3%

P/S0.6×+0.1×

Profitability

See full

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

FCF margin-17%—

Returns & leverage

See full

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Myriad Genetics's share based compensation arrangement by share based payment award options exercisable number?: Myriad Genetics (MYGN) reported share based compensation arrangement by share based payment award options exercisable number of $500K in Q1 2026.
How has Myriad Genetics's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?: Myriad Genetics's share based compensation arrangement by share based payment award options exercisable number decreased by 0.0% year-over-year, from $500K to $500K.